Calculation of productions of medical 201Pb, 198Au, 186Re, 111Ag, 103Pd, 90Y, 89Sr, 77Kr, 77As, 67Cu, 64Cu, 47Sc and 32P nuclei used in cancer therapy via phenomenological and microscopic level density models

In the present study, we have widely investigated the production of nuclei used in cancer therapy for both phenomenological and microscopic level density models via TALYS and EMPIRE codes. To estimate the production of the radioisotope, we calculated the cross-section curves of the reaction and the integral yield curves for nine level density models using the cross-sections and the mass-stopping powers acquired from X-PMSP program in the particle beam current of 1 µA and irradiation time 1 h. To discuss the obtained results on the basis of the cross-sections and the integral yields curves, the results were compared with the experimental data and the recommended data in the literature. © 2018 Elsevier Ltd

Yazar Artun O.
Yayın Türü Article
Tek Biçim Adres https://hdl.handle.net/20.500.12628/4555
Tek Biçim Adres 10.1016/j.apradiso.2018.11.011
Konu Başlıkları Level density models
Radioisotope production
Therapy
Yield
Koleksiyonlar Araştırma Çıktıları | WoS | Scopus | TR-Dizin | PubMed | SOBİAD
Scopus İndeksli Yayınlar Koleksiyonu
Dergi Adı Applied Radiation and Isotopes
Dergi Cilt Bilgisi 144
Sayfalar 64 - 79
Yayın Yılı 2019
Eser Adı
[dc.title]
Calculation of productions of medical 201Pb, 198Au, 186Re, 111Ag, 103Pd, 90Y, 89Sr, 77Kr, 77As, 67Cu, 64Cu, 47Sc and 32P nuclei used in cancer therapy via phenomenological and microscopic level density models
Yazar
[dc.contributor.author]
Artun O.
Yayın Yılı
[dc.date.issued]
2019
Yayıncı
[dc.publisher]
Elsevier Ltd
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
In the present study, we have widely investigated the production of nuclei used in cancer therapy for both phenomenological and microscopic level density models via TALYS and EMPIRE codes. To estimate the production of the radioisotope, we calculated the cross-section curves of the reaction and the integral yield curves for nine level density models using the cross-sections and the mass-stopping powers acquired from X-PMSP program in the particle beam current of 1 µA and irradiation time 1 h. To discuss the obtained results on the basis of the cross-sections and the integral yields curves, the results were compared with the experimental data and the recommended data in the literature. © 2018 Elsevier Ltd
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Konu Başlıkları
[dc.subject]
Level density models
Konu Başlıkları
[dc.subject]
Radioisotope production
Konu Başlıkları
[dc.subject]
Therapy
Konu Başlıkları
[dc.subject]
Yield
Haklar
[dc.rights]
info:eu-repo/semantics/closedAccess
ISSN
[dc.identifier.issn]
0969-8043
İlk Sayfa Sayısı
[dc.identifier.startpage]
64
Son Sayfa Sayısı
[dc.identifier.endpage]
79
Dergi Adı
[dc.relation.journal]
Applied Radiation and Isotopes
Dergi Cilt Bilgisi
[dc.identifier.volume]
144
Tek Biçim Adres
[dc.identifier.uri]
https://dx.doi.org/10.1016/j.apradiso.2018.11.011
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/4555
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
109
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
14 Haziran 2024 13:52
Google Kontrol
Tıklayınız
curves integral cross-sections results models density production compared program Elsevier particle current irradiation literature discuss obtained recommended experimental yields X-PMSP acquired microscopic present widely investigated nuclei cancer therapy phenomenological powers EMPIRE estimate radioisotope calculated cross-section
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms